Novo Nordisk's pricing strategies inside the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who may have accused the company of selling price gouging, mentioning the stark contrast involving U.S. charges and people in Europe and copyright.This led Novo Nordisk to conduct further investigation into larger dosages of semaglutide